Morgan Stanley raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $129 from $122 and keeps an Overweight rating on the shares. The firm believes commercial experience in Bardet-Biedl syndrome sets the stage for “meaningful label expansion” in hypothalamic obesity later this year, noting that the company has an associated PDUFA deadline of December 20.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Buy Rating for Rhythm Pharmaceuticals: Promising Setmelanotide Efficacy and Market Potential in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $110 from $100 at H.C. Wainwright
- Rhythm Pharmaceuticals price target raised to $142 from $135 at Citizens JMP
- Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating
- Rhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley